More articles from Moving Points in Nephrology

You have accessRestricted Access
FDA Regulatory Perspectives for Studies on Hemodialysis Vascular Access
Frank P. Hurst, Robert E. Lee, Aliza M. Thompson, Brian D. Pullin and Douglas M. Silverstein

CJASN March 2018, 13 (3) 513-518; DOI: https://doi.org/10.2215/CJN.02900317

Add to Selected Citations
You have accessRestricted Access
Recommended Clinical Trial End Points for Dialysis Catheters
Michael Allon, Deborah J. Brouwer-Maier, Kenneth Abreo, Kevin M. Baskin, Kay Bregel, Deepa H. Chand, Andrea M. Easom, Leonard Mermel, Michele H. Mokrzycki, Priti R. Patel, Prabir Roy-Chaudhury, Surendra Shenoy, Rudolph P. Valentini and Haimanot Wasse

CJASN March 2018, 13 (3) 495-500; DOI: https://doi.org/10.2215/CJN.12011116

Add to Selected Citations
You have accessRestricted Access
Clinical Trial End Points for Hemodialysis Vascular Access
Surendra Shenoy, Michael Allon, Gerald Beathard, Deborah Brouwer-Maier, Laura M. Dember, Mark Glickman, Celeste Lee, Terry Litchfield, Charmaine Lok, Thomas Huber, Prabir Roy-Chaudhury, Jack Work, Melissa West and Haimanot Wasse

CJASN March 2018, 13 (3) 490-494; DOI: https://doi.org/10.2215/CJN.13321216

Add to Selected Citations
You have accessRestricted Access
Definitions and End Points for Interventional Studies for Arteriovenous Dialysis Access
Gerald A. Beathard, Charmaine E. Lok, Marc H. Glickman, Ahmed A. Al-Jaishi, Donna Bednarski, David L. Cull, Jeffery H. Lawson, Timmy C. Lee, Vandana D. Niyyar, Donna Syracuse, Scott O. Trerotola, Prabir Roy-Chaudhury, Surendra Shenoy, Margo Underwood, Haimanot Wasse, Karen Woo, Theodore H. Yuo and Thomas S. Huber

CJASN March 2018, 13 (3) 501-512; DOI: https://doi.org/10.2215/CJN.11531116

Add to Selected Citations
You have accessRestricted Access
Paraprotein–Related Kidney Disease: Diagnosing and Treating Monoclonal Gammopathy of Renal Significance
Mitchell H. Rosner, Amaka Edeani, Motoko Yanagita, Ilya G. Glezerman and Nelson Leung

CJASN December 2016, 11 (12) 2280-2287; DOI: https://doi.org/10.2215/CJN.02920316

Add to Selected Citations
You have accessRestricted Access
Paraprotein–Related Kidney Disease: Kidney Injury from Paraproteins—What Determines the Site of Injury?
Mona Doshi, Amit Lahoti, Farhad R. Danesh, Vecihi Batuman and Paul W. Sanders

CJASN December 2016, 11 (12) 2288-2294; DOI: https://doi.org/10.2215/CJN.02560316

Add to Selected Citations
You have accessRestricted Access
Paraprotein–Related Kidney Disease: Attack of the Killer M Proteins
Mark A. Perazella and Kevin W. Finkel

CJASN December 2016, 11 (12) 2256-2259; DOI: https://doi.org/10.2215/CJN.02960316

Add to Selected Citations
You have accessRestricted Access
Paraprotein–Related Kidney Disease: Evaluation and Treatment of Myeloma Cast Nephropathy
Kevin W. Finkel, Eric P. Cohen, Anushree Shirali and Ala Abudayyeh

CJASN December 2016, 11 (12) 2273-2279; DOI: https://doi.org/10.2215/CJN.01640216

Add to Selected Citations
You have accessRestricted Access
Paraprotein–Related Kidney Disease: Glomerular Diseases Associated with Paraproteinemias
Shveta S. Motwani, Leal Herlitz, Divya Monga, Kenar D. Jhaveri and Albert Q. Lam

CJASN December 2016, 11 (12) 2260-2272; DOI: https://doi.org/10.2215/CJN.02980316

Add to Selected Citations
You have accessRestricted Access
Supportive Care: Comprehensive Conservative Care in End-Stage Kidney Disease
Fliss E.M. Murtagh, Aine Burns, Olivier Moranne, Rachael L. Morton and Saraladevi Naicker

CJASN October 2016, 11 (10) 1909-1914; DOI: https://doi.org/10.2215/CJN.04840516

Add to Selected Citations

Main menu

User menu

Search

More articles from Moving Points in Nephrology

Pages

Articles

Information for Authors

About

Journal Information

More Information